Volume No. :   1

Issue No. :  3

Year :  2011

ISSN Print :  2231-5640

ISSN Online :  2231-5659


Registration

Allready Registrered
Click to Login

Dealing With the Challenges during Large Scale Manufacturing of Polymorphic Drug Substances



Address:   Sudhir Sawant* and Ramesh Yamgar
P. G. Dept of Chemistry, Govt. of Maharashtra’s Ismail Yusuf College of Arts, Science and Commerce, Jogeshwari (East), Mumbai 400 060 INDIA
*Corresponding Author
DOI No:

ABSTRACT:
This paper will discuss the various risks and challenges that manufacturers face regarding the manufacturing of polymorphically pure products especially APIs and detailed specific risks during manufacturing in commercial plants and precautions to be taken during manufacturing, quality inspections and also during their product development efforts in R and D. A conscious approach of all personnel involved in manufacturing teams towards ensuring the polymorphic purity of the drug substance is very much essential element for regulated markets and for business continuity of a generic firm.
KEYWORDS:
Polymorphs, drug substance, bioavailability, bioequivalence, dissolution, recrystallisation, XRPD, manufacturing, regulatory agencies, DMF, ANDA
Cite:
Sudhir Sawant, Ramesh Yamgar. Dealing With the Challenges during Large Scale Manufacturing of Polymorphic Drug Substances. Asian J. Res. Pharm. Sci. 1(3): July-Sept. 2011; Page 63-68.
[View HTML]      [View PDF]



Visitor's No. :   93048